AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

AbbVie has agreed to buy Apogee Therapeutics for $10.9 billion in cash, a move that would add a late-stage immunology asset to the drugmaker’s pipeline as it keeps building beyond Humira.

The transaction was reported by multiple outlets on June 22, 2026, and values Apogee at $135.11 a share. That price implies a premium of about 49% to Apogee’s prior close, underscoring how aggressively AbbVie is willing to pay for a nearer-term growth opportunity.

Apogee’s lead program is zumilokibart, an experimental drug candidate being developed for atopic dermatitis. AbbVie is buying into a therapy area where it already competes with products such as Skyrizi and Rinvoq, and where demand for new treatments remains strong.

Why AbbVie is making the deal

The acquisition fits AbbVie’s broader immunology strategy. As Humira faces biosimilar competition after patent expiry, the company has been leaning on newer products and looking for additional pipeline depth in inflammatory disease.

That makes Apogee a strategic fit rather than just a financial purchase. AbbVie is using cash to secure an asset that could matter commercially sooner than an early-stage internal program, while also broadening its presence in a market where it already has meaningful exposure.

The deal is also notable for its size. One report described it as AbbVie’s largest acquisition in more than five years, which reflects both the scale of the bet and the pressure large drugmakers face to keep replenishing their pipelines.

What Apogee brings

Apogee is a biotechnology company focused on inflammatory disease candidates. Its best-known asset in this deal is zumilokibart, which has become the centerpiece of the acquisition.

Atopic dermatitis is an especially competitive corner of immunology, but it is also a large one, and AbbVie appears to be wagering that a late-stage asset can strengthen its position in a category where it already has commercial scale.

The transaction gives AbbVie a way to diversify future growth away from older revenue streams and toward a broader mix of immunology products. It also shows a preference for buying pipeline risk rather than waiting for it to play out internally.

Deal terms and timing

Barron’s reported that both boards approved the transaction and that closing is targeted for the third quarter of 2026. Those reports also said the deal still needs the usual remaining steps, including regulatory and shareholder approvals.

For now, the main open questions are the same ones that typically follow a large pharma acquisition: when the companies file full merger documents, whether they disclose financing details, and what AbbVie says about any earnings or integration impact.

Any official filing could also clarify closing conditions and help investors assess how the deal affects AbbVie’s near-term financial outlook.

What to watch next

The most immediate next step is formal disclosure from the companies, especially if they publish merger terms or related filing documents. Investors will be looking for confirmation on timetable, conditions and any additional commentary from AbbVie management.

The market will also watch for signs of how much confidence AbbVie has in zumilokibart’s commercial potential and where the drug fits alongside Skyrizi and Rinvoq in the company’s broader immunology portfolio.

For Apogee shareholders, the headline is simpler: the agreed cash price delivers a sizable premium if the deal closes. For AbbVie, the acquisition is a reminder that the company is still willing to spend heavily to reinforce a core franchise that has become even more important after Humira.

,